ABCL 575
Alternative Names: ABCL-575Latest Information Update: 13 Aug 2024
At a glance
- Originator EQRx
- Developer Abcellera
- Class Anti-inflammatories; Antiasthmatics; Antibodies; Skin disorder therapies
- Mechanism of Action OX40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alopecia areata; Asthma; Atopic dermatitis; Hidradenitis suppurativa
Most Recent Events
- 06 Aug 2024 AbCellera announces intention to submit Clinical Trial Applications for Atopic dermatitis in second quarter of 2025 (AbCellera pipeline, January 2024)
- 24 Jan 2024 AbCellera plans a clinical trial for Atopic dermatitis in 2025
- 17 Jan 2024 ABCL 575 is available for licensing as of 17 Jan 2024 (AbCellera website, January 2024)